The AI race heats up with a new kid on the block from China. How did it compare against a popular U.S. genAI engine on a simple healthcare industry question?
Quibim's technology applies artificial intelligence analysis to medical images to detect biomarkers. Hospitals and biopharma companies are among the startup's customers, using its technology to analyze images to detect disease and guide clinical trial enrollment.
Akero Therapeutics reported that at 96 weeks, 39% of patients who received the 50 mg dose of efruxifermin achieved improvement in fibrosis, or liver scarring, caused by the fatty liver disease MASH. This study previously failed to achieve statistically significant improvement at 36 weeks, but Akero executives say the latest results show that longer dosing matters.
The transition to hybrid measures in 2024 has been more than just a regulatory requirement — it's been a catalyst for meaningful change in how we approach quality reporting. Here are five critical insights that can help healthcare organizations comply with requirements and excel in their quality reporting journey.
The shifting AI landscape. Learn about the emerging technologies from AI tech developers across the healthcare landscape from health tech startups to healthcare organizations, biopharma companies, and a medtech giant.
Post Comment
No comments